FDA Panel Unanimously Rejects ALS Cell Therapy: A Setback for Patients and Research

FDA Panel Votes Against Investigational ALS Treatment Introduction In a blow to patients and researchers alike, nearly all members of the FDA‘s Cellular, Tissue, and Gene Therapy Advisory Committee voted against the data presented for an investigational amyotrophic lateral sclerosis (ALS) treatment. This decision, which came in a 17-1 vote, stated that the data presented […]